Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + GM-CSF in advanced biliary cancers
NCT02703714Phase 2Completed
- Start
- May 2016
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in biliary cancer. Primary endpoint: Overall Response Rate at 2 years. Started May 2016; status: completed.
02
Drugs
03
Conditions
biliary cancer
Beyond the preview
Go deeper on NCT02703714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02703714.